Clinical Trials on Gastric Cancer With Peritoneal Dissemination in Hong Kong

Total 72 results

Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer

Gastric Cancer

United States
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, India, Taiwan, Thailand, Hong Kong, Japan, Switzerland, Poland
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

Gastric Cancer | Esophageal Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
Amgen

Terminated

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, Belgium, Germany, Italy, United Kingdom, Canada, Denmark, Switzerland, Hong Kong, Austria, Slovakia, Taiwan, Hungary, France, Singapore, Australia, Poland, New Zealand
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer

United States, Canada
Boehringer Ingelheim

Completed

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Amgen

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Austria, Belgium, Italy, Netherlands, Spain, Canada, Denmark, Germany, Korea, Republic of, Russian Federation, Hong Kong, Greece, Japan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
Ellipses Pharma

Withdrawn

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Gastric Cancer | Small-cell Lung Cancer

China, Korea, Republic of, Taiwan
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Pfizer

Completed

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Hepatocellular Carcinoma | Advanced Breast Cancer | Non-Small Cell Lung Cancer | Metastatic Breast Cancer | Metastatic Renal Cell Cancer | Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Gastrointestinal Stromal Tumor | Advanced Gastric Cancer | Metastatic Castration Resistant Prostate Cancer | Advanced... and other conditions

United States, Spain, Korea, Republic of, France, Australia, United Kingdom, Canada, Brazil, Argentina, Taiwan, Belgium, Colombia, Germany, Hong Kong, Mexico, Philippines, Singapore
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Israel, Italy, Spain, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, China, Belgium, Poland, Thailand, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Melanoma | Sarcoma | Acute Myeloid Leukemia | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Stage III Pancreatic... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam

Clinical Trials on Gastric Cancer With Peritoneal Dissemination in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations